Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical hormones” means the hormone molecules are chemically identical to the hormones your body makes (usually estradiol, estrone, progesterone, testosterone).
• “Standard” HRT (hormone replacement therapy) usually refers to FDA‑approved hormone products that may be either bioidentical (e.g., estradiol, micronized progesterone) or synthetic/progestin formulations (e.g., conjugated equine estrogens, medroxyprogesterone). The main practical differences are how the products are made, regulated, and studied—not a guaranteed difference in safety or effectiveness.

Details — key differences

• Composition
  • Bioidentical: molecules match human hormones (examples: estradiol, micronized progesterone). Compounded bioidentical hormone therapy (CBHT) is custom‑mixed by compounding pharmacies and often marketed as “natural” or individualized (e.g., Biest, Triest, custom progesterone doses).
  • Standard HRT: includes FDA‑approved products. Some are bioidentical (FDA‑approved estradiol and micronized progesterone), others are synthetic (conjugated equine estrogens like Premarin, progestins like medroxyprogesterone).
• Regulation and quality control
  • FDA‑approved HRT products have standardized doses, consistent manufacturing, and safety/efficacy data from trials.
  • Compounded bioidentical hormones are not FDA‑approved, so batch‑to‑batch consistency and dosing can vary. Quality depends on the compounding pharmacy’s processes.
• Evidence and safety
  • There’s no convincing evidence that compounded bioidentical hormones are safer or more effective than FDA‑approved hormone products. Risks (breast cancer, blood clots, stroke, heart disease) relate to the hormones themselves and the dose, route, and patient risk factors.
  • Some forms/routes have different risk profiles: transdermal estradiol (patch/gel) appears to have lower venous thromboembolism (VTE) risk than some oral estrogens. Micronized progesterone (Prometrium) may have a different risk profile than synthetic progestins.
• Monitoring and testing
  • Routine salivary hormone testing is not a reliable way to guide dosing. Dose should be based on symptoms, risk factors, and blood levels where appropriate.

Practical examples and brand names

• FDA‑approved bioidentical options (well‑studied, standardized):
  • Estradiol patches: Vivelle‑Dot, Climara, Alora — convenient, steady dosing; transdermal route may lower VTE risk.
  • Estradiol gel/cream: EstroGel, Divigel — topical option.
  • Oral estradiol: Estrace (micronized estradiol).
  • Micronized progesterone: Prometrium — bioidentical progesterone available as an FDA‑approved oral product used for endometrial protection when needed.
• Non‑bioidentical (synthetic) examples:
  • Conjugated equine estrogens: Premarin.
  • Progestin: medroxyprogesterone acetate (Provera).
• Compounded BHRT: examples include custom mixtures called “Biest” or “Triest” (combinations of estradiol/estriol/estrone) or individualized progesterone creams — these are made by compounding pharmacies and are not FDA‑approved.

When you might choose one over the other

• Choose FDA‑approved products when possible for predictable dosing, documented safety/efficacy, and established monitoring.
• Compounded BHRT may be considered if you have a true intolerance/allergy to an ingredient in commercial products or need a dose/formulation not available commercially — but only from a reputable, accredited compounding pharmacy and with careful follow‑up.
• For women with a uterus, any estrogen therapy should include appropriate progestogen to reduce endometrial cancer risk.

Recommendations / next steps

• Discuss goals and risks with a clinician who knows menopause/HRT (gynecologist, menopause specialist, reproductive endocrinologist).
• Prefer FDA‑approved estradiol and micronized progesterone products when possible for consistency and safety data.
• If considering compounded BHRT, use a compounding pharmacy that follows USP standards and has accreditation (ask about quality control and testing), and arrange follow‑up for symptom response and safety monitoring.
• Use the lowest effective dose for the shortest time needed and reassess periodically. Screen as appropriate (mammography, bone density, cardiovascular risk assessment).

If you want, tell me:

• Are you asking for menopausal symptoms, low testosterone, or gender-affirming care?
• Any medical history (blood clots, breast cancer, liver disease)? I can give more tailored information.